Skip to content
Menu

Kodiak Sciences Inc. KOD

Full chart Compare
Set alert

Price alert · KOD

All alert types
97.25 USD -0.65 (-0.66%)

As ofNov 20, 2026, 3:43 PM EST

96.53 Day range 100.89
19.25 52-week range 112.79
YTD
+247.82%
1 year
+396.43%

5D -11.53 (-10.55%)

95100105110MonTueWedThuFri97.75
Market cap
6.36B
EPS (ttm)
-4.08
Shares out
65.40M
Forward P/E
-28.00
YTD return
+247.82%
1-year return
+396.43%
50-day average
80.54
200-day average
47.05
Enterprise value
6.34B
Price / book
499.49
Volume
461.26K
Avg volume
1.76M
Open
97.39
Previous close
97.90
Day's range
96.53 – 100.89
52-week range
19.25 – 112.79
Beta
1.98
Analysts
Strong Buy
Price target
130.17 (+33.8%)
Earnings date
Mar 30, 2027

Key statistics

Free cash flow
-70.67M
Total cash
88.68M
Total debt
46.56M
Return on equity
-1360.91%
Short % of float
19.71%

Fundamental scorecard

2 of 25 checks passed on KOD’s reported financials

ValueGrowthProfitabilityHealthDividend

2of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
KOD Revenue — quarterly 0
KOD Net income — quarterly -66.22M
KOD EPS — quarterly -1.05

Earnings

KOD recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 30, 2027Dec 30, 2026-1.00———
Nov 12, 2026Sep 30, 2026-1.06-1.05+0.01+0.94%
Aug 12, 2026Jun 30, 2026-0.95647-1.05-0.09-9.78%
May 7, 2026Mar 31, 2026-0.93-0.94-0.01-1.08%
Mar 31, 2026Dec 31, 2025-1.02-1.04-0.02-1.96%
Nov 13, 2025Sep 30, 2025-1.07-1.16-0.09-8.41%

Upgrades / downgrades

KOD analyst upgrades and downgrades
DateFirmActionFromTo
Oct 12, 2026HC Wainwright & Co.mainBuyBuy
Sep 28, 2026LifeSci CapitalmainOutperformOutperform
Sep 28, 2026UBSmainBuyBuy
Sep 28, 2026HC Wainwright & Co.mainBuyBuy
Sep 17, 2026HC Wainwright & Co.reitBuyBuy
Aug 17, 2026HC Wainwright & Co.reitBuyBuy

About Kodiak Sciences Inc.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
kodiak.com

News

Your note

Sign in to keep a note on KOD — it syncs with the Stock Master app.

Insider holders

KOD insider holders
InsiderRelationLatest transactionDateShares held
BAKER BROS ADVISORS L.P.Beneficial Owner of more than 10% of a Class of SecurityPurchaseSep 28, 20260
BORGESON JOHN AChief Financial OfficerSaleJun 3, 2026211,930
PERLROTH VICTOR DChief Executive OfficerConversion of Exercise of derivative securitySep 24, 20263,676,060
YANG TAIYINDirectorConversion of Exercise of derivative securityOct 22, 202620,000

Institution ownership

KOD institution ownership
Holder% heldSharesValueReported
Baker Bros. Advisors, LP33.43%21,860,9412.14BSep 29, 2026
Blackrock Inc.5.83%3,813,908373.38MSep 29, 2026
Price (T.Rowe) Associates Inc4.49%2,933,627287.20MSep 29, 2026
State Street Corporation3.41%2,229,245218.24MSep 29, 2026
Goldman Sachs Group Inc3.04%1,990,315194.85MSep 29, 2026
T. Rowe Price Investment Management, Inc.3.01%1,971,021192.96MSep 29, 2026

Fund ownership

KOD fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund1.97%1,288,755126.17MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.96%1,281,918125.50MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF1.57%1,024,195100.27MSep 29, 2026
T. Rowe Price Health Sciences Fund, Inc.1.55%1,013,71199.24MJun 29, 2026
Artisan Partners Funds Inc.-Artisan International Small-Mid Fund0.91%595,99158.35MJun 29, 2026
T. Rowe Price New Horizons Fund, Inc.0.90%590,81657.84MJun 29, 2026